stockmarket

Biomarin Pharma Earnings beat, Revenue misses In Q3


Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday third quarter that beat analysts’ forecasts and revenue that fell short of expectations.

Biomarin Pharma announced earnings per share of $-0.2 on revenue of $408.7M. Analysts polled by Investing.com anticipated EPS of $-0.2427 on revenue of $435.89M.

Biomarin Pharma shares are down 18.21% from the beginning of the year and are trading at $71.50 , down-from-52-week-high.They are under-performing the Nasdaq which is up 18.21% from the start of the year.

Biomarin Pharma shares lost 0.31% in after-hours trade the report.

Biomarin Pharma follows other major Healthcare sector earnings this month

Biomarin Pharma’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.33B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.